NEW YORK (360Dx) – Novacyt said this week that its revenue from continuing operations for full-year 2018 will be in the range of €13.7 million to €14.4 million ($17.4 million to $18.3 million), following its decision in December to sell its Novaprep cytology business and clinical laboratory operations. That estimate, which includes revenues from the company's Primerdesign and Lab21 diagnostic reagent units, compares to a market consensus of €15.9 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.